Molecular neuroimaging in degenerative dementias;La neuroimagen molecular en las demencias degenerativas

Revista Espanola de Medicina Nuclear e Imagen Molecular

Volumn 32, Issue 5, 2013, Pages 301-309

  Jimenez Bonilla J F ^a   Carril Carril, J M ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

11C PIB; Alzheimer's disease; Amyloid imaging; Dementia; Molecular imaging; Positron emission tomography

Indexed keywords

CARBON 11; FLUORINE 18;

ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; BRAIN PERFUSION; CYCLOTRON; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; IN VIVO STUDY; LONGITUDINAL STUDY; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

(11)C-PIB; ALZHEIMER'S DISEASE; AMYLOID IMAGING; DEMENCIA; DEMENTIA; ENFERMEDAD DE ALZHEIMER; IMAGEN DE AMILOIDE; IMAGEN MOLECULAR; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; TOMOGRAFÍA DE EMISIÓN DE POSITRONES;

AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BENZOTHIAZOLES; BRAIN; CARBON RADIOISOTOPES; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; ETHYLENE GLYCOLS; FLUORINE RADIOISOTOPES; FORECASTING; MOLECULAR IMAGING; NEURODEGENERATIVE DISEASES; NEUROFIBRILLARY TANGLES; NEUROIMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; STILBENES; TAU PROTEINS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84883293451     PISSN: 2253654X     EISSN: 22538070     Source Type: Journal    
DOI: 10.1016/j.remn.2013.06.012     Document Type: Article

References (63)

1. Norton S., Matthews F., Brayne C. A commentary on studies presenting projections of the future prevalence of dementia. BMC Public Health 2013, 13:1.
2. World population to 2300 2004, United Nations, United Nations, New York.
3. Reitz C., Brayne C., Maveaux R. Epidemiology of Alzheimer disease. Nat Rev Neurol 2011, 7:137-152.
4. Levy J.A., Chelune G.J. Cognitive-behavioral profiles of neurodegenerative dementias: Beyond Alzheimer's disease. J Geriatr Psychiatry Neurol 2007, 20:227-238.
5. Victoroff J., Mack W.J., Lyness M.A., Chui H.C. Multicenter clinicopatological correlation in dementia. Am J Psychiatry 1995, 152:1476-1484.
6. Carril J.M., MacDonald A.F., Dendy P.P., Keyes W.I., Undrill P.E., Mallard J.R. Cranial scintigraphy: Value of adding emission computed tomographic sections to conventional pertechnetate images (512 cases). J Nucl Med 1979, 20:1117-1123.
7. Andersen A.R. 99mTc -D, L-hexamethyllene-propyleneamine oxime (99mTc-HMPAO): Basic kinetic studies of a tracer of cerebral blood flow. Cerebrovasc Brain Metab Rev 1989, 1:288-318.
8. Heiss W.D., Herholz K., Podreka I., Neubauer I., Pietrzyk U. Comparison of 99mTcHMPAO SPECT with 18F-fluoromethane PET in cerebrovascular disease. J Cereb Blood Flow Metab 1990, 10:687-697.
9. Banzo I., Quirce R., Martínez-Rodríguez I., Jiménez-Bonilla J., Portilla- Quattrociocchi H., Medina-Quiroz P., et al. Molecular neuroimaging in the study of cognitive impairment: Contribution of the cerebral blood flow SPECT with 99mTc-HMPAO and 18F-FDG PET/CT scan. Rev Esp Med Nucl 2011, 30:301-306.
10. Silverman D.H. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: Comparison with perfusion spect and with clinical evaluations lacking nuclear imaging. J Nucl Med 2004, 45:594-660.
11. Price J.C. Molecular brain imaging in the multimodality era. J Cereb Blood Flow Metab 2012, 32:1377-1392.
12. Mielke M.M., Lyketsos C.G. Alterations of the sphingolipid pathway in Alzheimer's disease: New biomarkers and treatment targets?. Neuromolecular Med 2010, 12:331-340.
13. Yokokura M., Mori N., Yagi S., Yoshikawa E., Kikuchi M., Yoshihara Y., et al. In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2011, 38:343-351.
14. Jack C.R., Lowe V.J., Weigand S.D., Wiste H.J., Senjem M.L., Knopman D.S., et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease. Brain 2009, 132:1355-1365.
15. Mankoff D.A. A definition of molecular imaging. J Nucl Med 2007, 48:18N-21N.
16. Jack C.R., Albert M.S., Knopman D.S., McKhann G.M., Sperling R.A., Carrillo M.C., et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:257-262.
17. McKhanna G.M., Knopmanc D.S., Chertkowd H., Hymanf B.T., Jack C.R., Kawash C.H., et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:263-269.
18. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:270-279.
19. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., et al. Towards defining the preclinical stage of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:280-292.
20. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984, 34:939-944.
21. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002, 297:353-356.
22. Ewers M., Sperling R.A., Klunk W.E., Weiner M.W., Hampel H. Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci 2011, 34:430-442.
23. Cohen A.D., Price J.C., Weissfeld L.A., James J., Rosario B.L., Bi W., et al. Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: An example of brain reserve. J Neurosci 2009, 29:14770-14778.
24. Herholz K., Carter S.F., Jones M Positron emission tomography imaging in dementia. Br J Radiol 2007, S160-S167.
25. Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., Cummings J., et al. Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 2007, 6:734-746.
26. Visser P.J., Vos S., van Rossum I., Scheltens P. Comparison of International Working Group criteria and National Institute on Aging-Alzheimer's Association criteria for Alzheimer's disease. Alzheimers Dement 2012, 8:560-563.
27. Johnson K.A., Minoshima S., Bohnen N.I., Donohoe K.J., Foster N.L., Herscovitch P., et al. Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging and the Alzheimer Association. J Nucl Med 2013, 54:476-490.
28. Booij J., Arbizu J., Darcourt J., Hesse S., Nobili F., Payoux P., et al. Appropriate use criteria for amyloid cannot replace guidelines: On behalf of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging 2013, 40:1122-1125.
29. Lockhart A. Imaging Alzheimer's disease pathology: One target, many ligands. Drug Discov Today 2006, 11:1093-1099.
30. Mattson M.P. Neurobiology: Ballads of a protein quartet. Nature 2003, 27:385-387.
31. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259.
32. Mathis C.A., Lopresti B.J., Klunk W.E. Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl Med Biol 2007, 34:809-822.
33. Shoghi-Jadid K., Small G.W., Agdeppa E.D., Kepe V., Ercoli L.M., Siddarth P., et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002, 10:24-35.
34. Mathis C.A., Wang Y., Holt D.P., Huang G.F., Debnath M.L., Klunk W.E. Syntesis and evaluation of 11C-labeled 6 - substituted 2 - arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003, 46:2740-2754.
35. Bacskai B.J., Hickey G.A., Skoch J., Kajdasz S.T., Wang Y., Huang G.F., et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding and clearance of an amyloyd-beta ligand in transgenic mice. Proc Natl Acad Sci U S A 2003, 100:12462-12467.
36. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburg Coumpound-B. Ann Neurol 2004, 55:306-319.
37. Nordberg A. PET imaging of amyloid in Alzheimer's disease. Lancet Neurol 2004, 3:519-527.
38. Price J.C., Klunk W.E., Lopresti B.J., Lu X., Hong J.A., Ziolto S.K., et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flor Metab 2005, 25:1528-1547.
39. Suotunen T., Hirvonen J., Immonen-Räiha P., Aalto S., Lisinen I., Arponen E., et al. Visual assessment of [(11) C] PIB PET in patients with cognitive impairment. Eur J Nucl Med Mol Imaging 2010, 37:1141-1147.
40. Rowe C.C., Villemagne V.L. Brain amyloid imaging. J Nucl Med 2011, 52:1733-1740.
41. Kemppainen N.M., Aalto S., Wilson I.A., Någren K., Helin S., Brück A., et al. Voxel-based analysis of PET amyloid ligand 11C PIB uptake in Alzheimer disease. Neurology 2006, 67:1575-1580.
42. McNamee R.L., Yee S.H., Price J.C., Klunk W.E., Rosario B., Weissfeld L., et al. Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. J Nucl Med 2009, 50:348-355.
43. Ikonomovic M.D., Klunk W.E., Abrahamson E.E., Mathis C.A., Price J.C., Tsopelas N.D., et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008, 131:1630-1645.
44. Ortega-Nava F., Jiménez-Bonilla J., Banzo I., Martínez-Rodríguez I., Rodríguez E., Mateo I., et al. Visual and semiquantitative assessment of [(11)C]PIB PET/CT in patients with cognitive impairment. Nucl Med Commun 2013, 34:367-368.
45. Wolk D.A., Price J.C., Saxton J.A., Snitz B.E., James J.A., Lopez O.L., et al. Amyloid Imaging in mild cognitive impairment subtypes. Ann Neurol 2009, 65:557-568.
46. Pike K.E., Savage G., Villemagne V.L., Ng S., Moss S.A., Maruff P., et al. Beta-amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer's disease. Brain J Neurol 2007, 130:2837-2844.
47. Li Y., Rinne J.O., Mosconi L., Pirraglia E., Rusinek H., DeSanti S., et al. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging 2008, 35:2169-2181.
48. Ortega-Nava F., Banzo I., Jiménez-Bonilla J., Martínez-Rodríguez I., Quirce R., de Arcocha M., et al. Contribution of 11C-PIB PET/CT and 18F-FDG PET/CT in the assessment of Alzheimer's disease. Nucl Med Commun 2012, 33:530.
49. Ossenkoppele R., Tolboom N., Foster-Dingley J.C., Adriaanse S.F., Boellard R., Yaqub M., et al. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. Eur J Nucl Med Mol Imaging 2012, 39:990-1000.
50. Jagust W.J., Bandy D., Chen K., Foster N.L., Landau S.M., Mathis C.A., et al. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement 2010, 6:221-229.
51. Rowe C.C., Ng S., Ackermann U., Gong S.J., Pike K., Savage G., et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007, 68:1718-1725.
52. Reiman E.M., Chen K., Liu X., Bandy D., Yu M., Lee W., et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 2009, 106:6820-6825.
53. Villemagne V.L., Pike K.E., Chetelat G., Ellis K.A., Mulligan R.S., Bourgeat P., et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 2011, 69:181-192.
54. Okello A., Koivunen J., Edison P., Archer H.A., Turkheimer F.E., Narren K., et al. Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study. Neurology 2009, 73:754-760.
55. Forsberg A., Engler H., Almkvist O., Blomquist G., Hagman G., Wall A., et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008, 29:1456-1465.
56. Ortega-Nava F., Martínez-Rodríguez I., de Arcocha-Torres M., Rodríguez E., Mateo I., Carril J.M. Amyloid PET imaging with 11C-PIB in two patients with cognitive impairment. Rev Esp Med Nucl Imagen Mol 2012, 31:40-41.
57. Gelosa G., Brooks D.J. The prognostic value of amyloid imaging. Eur J Nucl Med Mol Imaging 2012, 39:1207-1219.
58. Agdeppa E.D., Kepe V., Petri A., Satyamurthy N., Liu J., Huang S.C., et al. In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malononitrile. Neuroscience 2003, 117:723-730.
59. Vandenberghe R., van Laere K., Ivanoiu A., Salmon E., Bastin C., Triau E., et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Ann Neurol 2010, 68:319-329.
60. Rowe C.C., Ackermann U., Browne W., Mulligan R., Pike K.L., O'Keefe G., et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: Proof of mechanism. Lancet Neurol 2008, 7:129-135.
61. Wong D.F., Rosenberg P.B., Zhou Y., Kumar A., Raymont V., Ravert H.T., et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir (corrected) F 18). J Nucl Med 2010, 51:913-920.
62. Johnson K.A., Fox N.C., Sperling R.A., Klunk W.E. Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med 2012, 2. a006213.
63. Carter S.F., Schöll M., Almkist O., Wall A., Engler H., Lanstrom B. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: A multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med 2012, 53:37-46.